Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts-Reference-Cited by-同舟云学术

Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts

Published:2019-12 Issue:12 Volume:33 Page:14717-14733
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:The FASEB Journal

Author:

Cáceres Felipe Tapia¹,Gaspari Tracey A.¹,Samuel Chrishan S.¹²,Pinar Anita A.¹

Affiliation:

1. Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia;

2. Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, Victoria, Australia

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Reference55 articles.

1. Mechanisms of fibrosis: therapeutic translation for fibrotic disease

2. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities

3. Molecular physiology of cardiac regeneration

4. The Biological Basis for Cardiac Repair After Myocardial Infarction

5. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induced pluripotent stem cell-derived mesenchymal stem cells reverse bleomycin-induced pulmonary fibrosis and related lung stiffness;Biomedicine & Pharmacotherapy;2024-09

2. Integrative transcriptomics and proteomics analysis reveal the protection of Astragaloside IV against myocardial fibrosis by regulating senescence;European Journal of Pharmacology;2024-07

3. Involvement of oxidative stress-AMPK-Cx43-NLRP3 pathway in extracellular matrix remodeling of gastric smooth muscle cells in rats with diabetic gastroparesis;Cell Stress and Chaperones;2024-06

4. The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin;Biochemical Pharmacology;2024-05

5. Mechanism of NLRP3 Activation, Associated Cardiovascular Complications and Update on its Inhibitors Acting as Cardioprotective Agents;The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response;2024-04-02